Why Big Pharma Free Rides on Nature While the Cali Fund Sits Near Empty

Why Big Pharma Free Rides on Nature While the Cali Fund Sits Near Empty

Seven thousand dollars. That's roughly what the Cali Fund had pulled in by October 2026, despite being set up to raise around $1 billion a year from industries that profit from nature's genetic data.

Let that sink in. Drugmakers bring in hundreds of billions in revenue every year, and scientists routinely scan digital sequence information (DSI) from plants, microbes, and wild organisms to discover new compounds and therapies. Yet the global mechanism designed to channel a share of those commercial gains back toward biodiversity conservation—and the communities protecting those ecosystems—has barely gotten off the ground. Critics call it free-riding on nature. Honestly, it's hard to argue with the label when a flagship fund meant to reach a billion-dollar pace is sitting on a tiny fraction of that.

http://googleusercontent.com/lmdx_content/nllOvkeeVijtpiBYAUXjjspsZcMzMzkDSAKeZeybaPgyEfavTCtKAMnUDIyjpqZWDYRUmctJnYtakSUumJuuPtELjqqgkpGLtXWowILYbjTiSSARJDVcMDANRsRracadgjtZNYpLsPUzvyaNYvFddFmZIykj2297


How Drug Discovery Uses Nature's Genetic Data Without Paying Up

Modern biotech and pharmaceutical research don't always require a researcher to fly into a rainforest with a machete and a sample vial anymore. Much of the heavy lifting happens digitally through digital sequence information—genetic and biological data stored in public databases that scientists can search, download, and model from a lab computer.

For decades, biodiversity-rich countries and Indigenous peoples argued that wealth extracted from biological resources rarely flowed back to the places keeping those species alive. The Cali Fund, created under the UN Convention on Biological Diversity (CBD) multilateral mechanism after COP15 and COP16 and launched in February 2025, was built to fix that imbalance. Instead of making public databases pay or locking up open science, the idea was that commercial companies using DSI—across pharmaceuticals, cosmetics, agriculture, and biotech—would contribute a share of profits or revenue.

Here's where things get messy. Once genetic data sits in open digital repositories, tracing a single sequence back to a specific forest, coral reef, or village isn't simple. Drug development takes years, dozens of screening steps, and synthetic tweaks. Industry groups point to that long chain of research to argue that tying commercial revenue directly to one sequence overstates what nature's data actually contributed.

Why Big Pharma Pushes Back Against the Cali Fund

If you read industry submissions and policy pushback, you'll see a very different framing than "free-riding". Pharmaceutical trade bodies, including the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), have pushed back against contribution formulas—such as benchmarks tied to a percentage of profit or revenue—arguing they act like a tax on innovation or overlap with existing rules.

From an executive's seat, R&D budgets are tight, clinical trials fail constantly, and small shifts in expected returns can delay or kill risky projects. Industry representatives also contend that revenue-based targets don't match how genetic data is actually used in modern drug discovery.

That argument isn't purely imaginary, even if critics view it as a convenient shield. Voluntary pledges in international treaties almost always struggle when there's no hard enforcement hammer behind them. When contributing is framed as voluntary or aspirational rather than mandatory law, a rational corporate finance team looks at the rules, sees no strict penalty for waiting, and holds cash until the rules are clearer—or never pays at all.

http://googleusercontent.com/lmdx_content/xUYdmtngEQokneVeZKuJVYiQjSnEbRrYwYkzLJqfaqHeeEWeIDvUUGRRTVZmMFkyAhDdSyIXruKyfGIuqSGjKGNtOzNZkWmBGOvacymgTKoeUGCnOaXqMyvgUCDBoRXwCxOgWsrRcZnjWmtAD2298


What the $7,000 Figure Really Means at COP17

A near-empty fund doesn't just look embarrassing at a UN summit; it exposes a structural flaw in voluntary global finance. At COP17 in Yerevan, Armenia, in October 2026, negotiators had to wrestle with both sides of the ledger: "money in" (why companies aren't paying and how contribution rates or certificates should work) and "money out" (how funds are allocated and disbursed).

Under the Cali Fund framework, at least 50% of funds are directed toward Indigenous peoples and local communities for their self-identified needs, with the rest supporting developing countries' national biodiversity strategies. That's a huge deal because Indigenous territories hold much of the world's remaining biodiversity, yet local groups often get shut out of direct conservation financing.

Still, money that hasn't arrived can't hire park rangers, restore degraded wetlands, or fund community-led protection. Some observers at COP17 warned that relying on corporate goodwill to close a massive global nature-financing gap leaves the fund vulnerable unless governments tighten rules or pair voluntary contributions with stronger incentives. Others counter that building trust, clear governance, and fair rules takes time—and rushing a flawed system won't bring big payers to the table either.

Common Myths About Genetic Data and Drug Profits

People often talk about nature and pharma as if every new pill comes straight out of a jungle leaf. Reality is more nuanced—and more interesting.

  • Myth: Every blockbuster drug comes directly from a single wild plant. Not quite. Many modern drugs are synthetically designed, engineered from microbial pathways, or inspired by known compounds rather than plucked whole from the wild. Yet digital sequence databases still help researchers compare structures, spot targets, and test biological mechanisms.
  • Myth: The Cali Fund shuts down free scientific research. It doesn't. Public access to genetic sequence data for research remains open, and non-commercial academic users aren't asked to make financial contributions under the mechanism, though non-monetary sharing like data access and capacity building is encouraged.
  • Myth: A $7,000 balance means biodiversity finance is dead. It means the DSI contribution model has a credibility and compliance problem right now. Governments, philanthropic groups, and public budgets still run parallel conservation programs, even if the gap to global nature targets remains huge.

Practical Steps for Tracking and Pushing Change

Whether you follow biotech policy, work in sustainability, or care about how global treaties turn promises into real dollars, you don't have to guess what's happening behind closed doors.

  1. Check official trust fund disclosures directly. Track actual inflows rather than press-release pledges by looking up the UN Multi-Partner Trust Fund Office Cali Fund portal and The Cali Fund COP17 updates.
  2. Watch the rules on certificates and compliance. Pay attention to how governments define contribution thresholds, certificates, and home-country enforcement—those details decide whether paying becomes standard practice or optional PR.
  3. Ask companies how they source biological data. If you evaluate biotech, cosmetics, or agricultural firms as an analyst, consumer, or advocate, look beyond broad "nature-positive" claims and ask how they handle DSI traceability and benefit-sharing.
  4. Support direct Indigenous and local conservation. Because half of the Cali Fund's intended disbursements target Indigenous peoples and local communities, backing organizations that channel direct funding to local stewards helps bridge the gap while global mechanisms sort out their growing pains.
EW

Ella Wang

A dedicated content strategist and editor, Ella Wang brings clarity and depth to complex topics. Committed to informing readers with accuracy and insight.